CytoGenix has successfully completed a pilot study with its synDNA vaccine which demonstrated its efficacy in protecting against the avian (H5N1) influenza virus.
Subscribe to our email newsletter
The study clearly demonstrated a robust protective effect in mice treated with the synDNA vaccine whereas all the untreated control animals died after both groups were challenged with a highly virulent strain of avian influenza virus. The lethal challenge testing was conducted by recognized collaborators in the field under a sponsored research agreement with the company.
“This novel DNA vaccine was produced using a unique combination of novel gene sequences and our proprietary synDNA production technology. We are extremely excited about this initial robust response in an animal challenge model,” stated Dr Yin Chen, chief scientific officer.